Compare CDMOs with mRNA manufacturing capabilities for vaccines, therapeutics, and gene editing applications. Filter by scale, LNP formulation expertise, and regulatory track record.
55 companies listed
mRNA manufacturing involves enzymatic in vitro transcription (IVT) to produce the mRNA molecule, followed by purification and formulation into lipid nanoparticles (LNPs) for delivery. The COVID-19 pandemic validated mRNA as a manufacturing platform, and now hundreds of mRNA programs are in development for infectious diseases, oncology, rare diseases, and protein replacement therapies.
The manufacturing process is cell-free, which is a fundamental advantage over traditional biologics. No cell culture or fermentation is required -- mRNA is synthesized enzymatically from a DNA template, purified chromatographically, and encapsulated in LNPs. This enables rapid campaign switching and shorter manufacturing timelines compared to monoclonal antibodies or viral vectors.
Germany
ReciBioPharm (now Recipharm Advanced Bio) is the advanced therapies division of Recipharm, a global CDMO devoted to process development and GMP manufacturing for advanced therapeutics including xRNA therapies, viral vectors, microbial/live biotherapeutic products, and recombinant proteins. They offer end-to-end services from preclinical development to commercial manufacturing, with operations on two continents. They have partnerships with the University of Oxford, NewBiologix (AAV cell lines), LenioBio, and Hongene Biotech.
United States
uBriGene Biosciences Inc is the same entity as uBriGene (duplicate entry, different ID). This is the China-headquartered entity of the same global CRDMO providing one-stop viral vector-based CDMO services for research and clinical applications. Series C+ funding of 150M CNY (~$20M USD). Same website, same capabilities. See uBriGene entry (ID 10a6a05c) for full details.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.